The University of California, Davis (UC Davis) and the University of Colorado Anschutz Medical Campus have received a $2.7m (~£2.15m) grant from the National Institute on...
Awakn Life Science’s study exploring the use of ketamine as a treatment for Gambling Disorder, Internet Gaming Disorder, Binge Eating Disorder and Compulsive Sexual Behavior is...
Beckley Psytech and Empatica are collaborating to support the collection and analysis of data in Beckley Psytech’s future clinical trials.
UK-based Beckley Psytech and drug discovery company Lophora ApS will be researching New Clinical Entities (NCE’s) to bolster a pipeline of next-generation psychedelic medicines.
UK-startup Clerkenwell Health is opening Europe’s first ever facility to host commercial psychedelic clinical trials in London.
As research into psychedelics continues to grow, a new peer reviewed scientific journal – Psychedelic Medicine – will be launched in 2023 to provide a high-profile...
CYB004 – which is being developed for anxiety disorders – has shown that it has a similar onset of effect and dose profile to IV DMT...
A Phase II trial is being conducted to investigate the potential of psilocybin-assisted psychotherapy as a treatment for binge eating disorder (BED).
With growing scientific interest in the area of psychedelics, Duke University has launched the Center for Integrated Psychedelic Science (CIPS).
Cybin has partnered with Clinilabs to carry out its Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analogue.